Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary

Br J Cancer. 2011 Aug 9;105(4):493-7. doi: 10.1038/bjc.2011.267. Epub 2011 Jul 19.


Background: The aim of this study was to determine the impact of lymphadenectomy and nodal metastasis on survival in clinical stage I malignant ovarian germ cell tumour (OGCT).

Methods: Data were obtained from the National Cancer Institute registry from 1988 to 2006. Analyses were performed using Student's t-test, Kaplan-Meier and Cox proportional hazard methods.

Results: In all, 1083 patients with OGCT who have undergone surgical treatment and deemed at time of the surgery to have disease clinically confined to the ovary were included 590 (54.48%) had no lymphadenectomy (LND-1) and 493 (45.52%) had lymphadenectomy. Of the 493 patients who had lymphadenectomy, 441 (89.5%) were FIGO surgical stage I (LND+1) and 52 (10.5%) were upstaged to FIGO stage IIIC due to nodal metastasis (LND+3C). The 5-year survival was 96.9% for LND-1, 97.7% for LND+1 and 93.4% for LND+3C (P=0.5). On multivariate analysis, lymphadenectomy was not an independent predictor of survival when controlling for age, histology and race (HR: 1.26, 95% CI: 0.62-2.58, P=0.5). Moreover, the presence of lymph node metastasis had no significant effect on survival (HR: 2.7, 95% CI: 0.67-10.96, P=0.16).

Conclusion: Neither lymphadenectomy nor lymph node metastasis was an independent predictor of survival in patients with OGCT confined to the ovary. This probably reflects the highly chemosensitive nature of these tumours.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Lymph Node Excision* / adverse effects
  • Lymph Node Excision* / methods
  • Lymph Nodes / pathology*
  • Lymph Nodes / surgery*
  • Lymphatic Metastasis
  • Middle Aged
  • Multivariate Analysis
  • National Cancer Institute (U.S.)
  • Neoplasm Staging
  • Neoplasms, Germ Cell and Embryonal / mortality*
  • Neoplasms, Germ Cell and Embryonal / pathology*
  • Neoplasms, Germ Cell and Embryonal / surgery
  • Ovarian Neoplasms / mortality*
  • Ovarian Neoplasms / pathology*
  • Ovarian Neoplasms / surgery
  • Predictive Value of Tests
  • Prognosis
  • Proportional Hazards Models
  • Registries
  • Retrospective Studies
  • Treatment Outcome
  • United States